Betta Pharmaceuticals enters hemophilia market with Sunshine Biopharma partnership

Betta Pharmaceuticals Co., Ltd. announced a strategic partnership with Sunshine Biopharma, including a "Strategic Cooperation Framework Agreement" and a "Commercial Cooperation Agreement." This collaboration positions Betta Pharmaceuticals to support Sunshine Biopharma in research, clinical trials, production, registration, and sales.

Under the "Commercial Cooperation Agreement," Betta Pharmaceuticals' wholly-owned subsidiary, Zhejiang Betta Medical Sales Co., Ltd., has obtained exclusive distribution rights in Greater China for FRSW117. FRSW117 is an injectable long-acting recombinant human coagulation factor VIII-Fc fusion protein, a Class 1 therapeutic biological product for routine prevention, on-demand treatment, and perioperative management of hemophilia A patients, with a projected dosing frequency of once a week.

This partnership aligns with Betta Pharmaceuticals' strategy to broaden its product portfolio and enter the recombinant blood factor market. While FRSW117 has not yet received marketing approval, the company anticipates no material adverse effects on its daily operations, financial performance, or overall independence, and current year's operating results will not be significantly impacted.